Verde Science, Inc.
VRCI
Other OTC0.00
USD
- -
- -
Verde Science, Inc.
VRCI
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Verde Science, Inc. Verde Science, Inc. (VRCI) is a pharmaceutical research and development company focused on developing a portfolio of cannabinoid-based prescription medicines for various medical conditions; its core offerings include medical marijuana products and related medical science consulting services. The company targets patients and clients in the burgeoning medicinal marijuana industry, providing technical and financial resources to support manufacturing, research, and development efforts in this sector. Founded in 2007 and headquartered in Dallas, Texas, Verde Science, Inc. formerly operated as Rango Energy, Inc., undergoing a name change and ticker symbol update to VRCI in May 2014 to reflect its strategic pivot to pharmaceutical innovation. No major acquisitions, partnerships, funding rounds, new product launches, or significant operational changes have been reported for the company in the last 1-2 years, with the most recent financial disclosures dating back to 2015 showing no revenue generation and ongoing net losses. Verde Science, Inc. maintains a minimal operational footprint with approximately one employee and continues to emphasize cannabinoid therapeutics amid a challenging financial profile, including a microcap market valuation under $25,000.
Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients
Verici Dx rises after passing key US laboratory accreditation audit
Verici Dx climbs on 'preferred provider' deal with US healthcare network
Verici Dx shares jump 23% as transplant test rollout gathers pace
Verici Dx plans fresh funding round to boost US test rollout
Verici Dx soars as Tutivia tests are confirmed by Medicare
Verici Dx says its seen a significant increase in Tutivia orders